Read This First
This page is not built on clinical evidence. Cost and access are commercial and legal facts, not scientific findings. They come from the regulatory record and the published literature on how this compound is sold, and they change on timescales of months.
Ipamorelin has no list price, no prescription route in the United States, no insurance pathway and no manufacturer, because it is not approved anywhere, both companies that developed it stopped, and it sits on the FDA's list of compounding substances that may present significant safety risks.1
This page publishes no prices. What follows is what determines the money, and for this compound the money is determined almost entirely by frequency.
Why There Is No Price
What a Price Normally Represents
For an approved medicine, a price sits on top of a known quantity of a known substance, made to a validated standard, for a stated indication, with a documented effect. Every element under the number is fixed.
For ipamorelin, none of that holds. There is no approved product, no manufacturing standard shared across sellers, and a documented tendency for retail product to be a different molecule from the one on the label.2 There is one documented effect in humans, a single growth hormone pulse lasting about an hour, and no measurement of what repeated pulses do to anything a buyer wants.3
Pricing a Pulse
This is the part of the compound's economics that per-vial figures conceal.
Ipamorelin's terminal half-life is two hours, and growth hormone after a dose peaks at 40 minutes and falls to negligible within a few hours.3 Community protocols therefore inject it two or three times a day, typically 200 to 300 micrograms each time, for cycles of eight to twelve weeks.4 At three injections a day, a nominal 5 mg vial lasts roughly a week. A twelve-week cycle at that rate is on the order of a dozen vials, before the CJC-1295 that is usually injected alongside it.
A vial price is therefore not a month's price, and a seller quoting one without the other is quoting the smaller number.
Access
Is There a Legal Route?
Not in the United States. Ipamorelin is not approved, is not a component of an approved drug, and is not on the 503A bulks list. It has never been before the Pharmacy Compounding Advisory Committee, and its stack partner CJC-1295 was rejected there unanimously in December 2024.5 As of April 2026 ipamorelin acetate remains in active Category 2 under the FDA's 503B policy, which means outsourcing facilities are specifically told not to compound it.1
There is no clinical trial to join. The last trial in patients, for postoperative ileus, completed in 2014 and nothing has been registered since.6
Does Insurance Cover It?
No, and there is nothing to appeal. Payers reimburse approved products for approved indications. With no approval anywhere there is no covered indication and no billing code attached to one.
Can HSA or FSA Funds Be Used?
Tax-advantaged health accounts cover qualified medical expenses, which generally requires a legitimate medical purpose and often a provider's documentation. A product that cannot lawfully be dispensed for human use sits poorly against that. The account holder carries the consequences of a disallowed expense; the question belongs with the plan administrator.
What About a "Peptide Clinic"?
A prescription cannot authorise what federal law does not permit to be compounded. The supply that clinics dispense comes from the same research-labelled channel as everything else, and a clinical setting makes an unlawful supply feel like a medical one without making it one. For ipamorelin specifically, the FDA has told outsourcing facilities not to make it; a clinic that says its supply is "pharmacy grade" should be asked which pharmacy.
What the Money Buys
Where Does the Spread Between Sellers Come From?
| Cost component | Present in | What it buys |
|---|---|---|
| Consultation and clinician time | Clinics, telehealth | A history, an examination, a record, and someone accountable |
| Premises, staff and liability | Clinics | Overhead and recourse, not product |
| Bundling into "CJC/Ipa" or a growth hormone protocol | Clinics, vendors | A second compound and a schedule, priced together so neither is examined alone |
| Injection frequency | All channels | Nothing; it multiplies the quantity consumed and is rarely stated in the headline figure |
| Marketing and affiliate commission | All channels, often invisible | Nothing for the buyer |
| The compound itself | All channels | Raw material of unverified identity, at a cost small relative to the components above it. ONPEPS publishes no prices; read this as reasoning about cost structure rather than a measured breakdown |
None of the spread buys verified product quality, because no channel offers that. A higher price buys service and accountability where those exist. It does not buy the molecule on the label, which for this compound has been shown to be a live question.7
Why Is the "Cleanest Secretagogue" Sold at a Premium?
Because it is the one thing about ipamorelin that is true and well documented. It raises growth hormone without raising cortisol or prolactin, where GHRP-2 and GHRP-6 raise both.8 That is a real pharmacological advantage over older secretagogues.
It is also an advantage in a comparison nobody is actually making. The alternative to ipamorelin for a person who wants a growth hormone effect is not GHRP-6; it is growth hormone itself, an approved drug with a defined dose and a measured effect, or tesamorelin, an approved GHRH analogue. Against those, "does not raise cortisol" is not a selling point; it is table stakes, and ipamorelin's lack of any efficacy data is the difference that matters.
The Spending Decision
What Result Is Being Paid For?
The product copy promises lean mass, fat loss, recovery and sleep through pulsatile growth hormone release. The mechanism is documented in healthy men after one dose.3 The outcomes have never been measured in a human being on this compound.
The one controlled animal comparison against growth hormone points the other way. In mice, twice-daily ipamorelin increased body fat, leptin and food intake by a mechanism independent of growth hormone, while growth hormone reduced fat.9 Ipamorelin is a ghrelin mimetic, and ghrelin is the hunger hormone. A buyer paying for fat loss is paying for a compound whose best-characterised non-pituitary effect is appetite.
A raised IGF-1 on a blood test after a few weeks confirms something active was in the vial. It does not confirm what, and it does not confirm the outcome the money was spent on.
What Is the Risk Side of the Ledger?
The human safety record is reassuring as far as it goes, and it does not go far: single intravenous doses in healthy men and a week of intravenous dosing in surgical patients.10 For subcutaneous use over months, the FDA states it has no safety information at all.1 The theoretical concern for the whole class, that sustained growth hormone and IGF-1 elevation may promote existing tumours, is unaddressed for this compound over any relevant timeframe.
And it is prohibited in sport under WADA section S2, with a validated urine test.11 For a tested athlete, that cost dwarfs the vial.
What Should Be Asked Before Paying?
What is the price per month at the injection frequency you recommend, for every component of the protocol?
Can I see a certificate of analysis matched to the batch I will receive, with the observed mass reported rather than "conforms"?
Are you aware the FDA lists this substance in Category 2 for outsourcing facilities, and on what legal basis are you supplying it?1
Which human study measured the outcome you are promising?
Does anyone here earn commission on product sales?
The fourth question has no answer, and a seller who supplies one is describing a study that does not exist.
What Would Change This Page
Approval, a Trial, or a Listing
None is in prospect. No company is developing ipamorelin, no trial is registered, and the FDA has not scheduled it for advisory review. The July 2026 advisory votes on other peptides did not include it and do not change its standing.12
A Note on "Cheaper Than Growth Hormone"
The comparison is common and it is not a comparison. Recombinant growth hormone is an approved drug with a defined dose, a measured effect and a known risk profile. Ipamorelin is an unverified substance sold on the premise that it produces some fraction of that effect. A price ratio between them says nothing about value, because the denominator has no measured effect to divide by. ONPEPS does not make the comparison.
Related ONPEPS Coverage
Ipamorelin library entry: the selectivity, the failed trials and the fat finding
Ipamorelin sourcing and quality: unnatural amino acids, glycine analogues and the 503B list
Sources
US Food and Drug Administration. Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Entries for ipamorelin acetate. Content current as of 22 April 2026. fda.gov
Krug O, Thomas A, Malerød-Fjeld H, Dehnes Y, Laussmann T, Feldmann I, et al. Analysis of new growth promoting black market products. Growth Horm IGF Res. 2018;41:1-6. Paywalled. pubmed.ncbi.nlm.nih.gov/29864719
Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. Paywalled. pubmed.ncbi.nlm.nih.gov/10496658
Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol (Lausanne). 2026;17:1822475. Open access. pubmed.ncbi.nlm.nih.gov/42395176
US Food and Drug Administration. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024. Approved 21 February 2025. fda.gov
ClinicalTrials.gov. NCT01280344. Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function. Sponsor Helsinn Therapeutics (U.S.), Inc. Phase 2, completed May 2014, no results posted. Record retrieved 16 September 2026. clinicaltrials.gov/study/NCT01280344
Gajda PM, Holm NB, Hoej LJ, Rasmussen BS, Dalsgaard PW, Reitzel LA, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal. 2019;11(2):350-354. Paywalled. pubmed.ncbi.nlm.nih.gov/30136411
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. Open access. pubmed.ncbi.nlm.nih.gov/9849822
Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280(1):132-138. Paywalled. pubmed.ncbi.nlm.nih.gov/11162489
Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. Paywalled. pubmed.ncbi.nlm.nih.gov/25331030
World Anti-Doping Agency. The Prohibited List, section S2. Current edition. wada-ama.org
US Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket FDA-2025-N-6895. fda.gov
Not Medical or Financial Advice
Ipamorelin is not approved for human use in any jurisdiction. Treatment decisions belong with a qualified healthcare provider. Nothing on this page is a recommendation to buy or not to buy anything; it is an account of what is known about what the money would be spent on.
Sources verified 16 September 2026. Regulatory status changes and a registered trial would change parts of this page. Re-verify before relying on anything here.